Roflumilast for the treatment of diabetes mellitus type 2

1. A pharmaceutical composition comprising a pharmaceutical formulation including a first amount of a compound of formula 1.1

or a pharmaceutically acceptable salt thereof and/or a compound of formula 1.2

or a pharmaceutically acceptable salt thereof, a second amount of a PPAR-agonist selected from the group consisting of MURAGLITAZAR, ROSIGLITAZONE, PIOGLITAZONE, RAGAGLITAZAR, FARGLITAZAR, TESAGLITAZAR, NAVEGLITAZAR, NETOGLITAZONE, RIVOGLITAZONE, K-111, GW-677954, FK-614, (−)-Halofenate and the pharmaceutically acceptable salts of these compounds, wherein the first amount and the second amount together comprise an effective amount for the treatment of diabetes mellitus type 2, and at least one pharmaceutically acceptable auxiliary.

2. The pharmaceutical composition according to claim 1 , wherein the PPAR-agonist is selected from the group consisting of PIOGLITAZONE and the pharmaceutically acceptable salts thereof.

3. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical formulation is a combination of Roflumilast and PIOGLITAZONE.

4. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical formulation is a combination of Roflumilast and a pharmaceutically acceptable salt of PIOGLITAZONE.

5. A method for treating diabetes mellitus type 2 comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutical formulation including a first amount of a compound of formula 1.1

or a pharmaceutically acceptable salt thereof and/or a compound of formula 1.2

or a pharmaceutically acceptable salt thereof, a second amount of a PPAR-agonist selected from the group consisting of MURAGLITAZAR, ROSIGLITAZONE, PIOGLITAZONE, RAGAGLITAZAR, FARGLITAZAR, TESAGLITAZAR, NAVEGLITAZAR, NETOGLITAZONE, RIVOGLITAZONE, K-111, GW-677954, FK-614, (−)-Halofenate and the pharmaceutically acceptable salts of these compounds, wherein the first amount and the second amount together comprise an effective amount for the treatment of diabetes mellitus type 2, and at least one pharmaceutically acceptable auxiliary.

6. The method according to claim 5 , wherein the PPAR-agonist is selected from the group consisting of PIOGLITAZONE and the pharmaceutically acceptable salts thereof.

7. The method according to claim 5 , wherein the pharmaceutical formulation is a combination of Roflumilast and PIOGLITAZONE.

8. The method according to claim 5 , wherein the pharmaceutical formulation is a combination of Roflumilast and a pharmaceutically acceptable salt of PIOGLITAZONE.